Merger arbitrage investors — fresh off a boom year for dealmaking — expect no let-up in the trend, with biotechnology firms seen as leading the pack among potential takeover candidates in the first quarter.
Merger Arbs See Wide-Open Deal Window With Biotech Top of List
